Monday, June 25, 2018

Arrowhead Pharmaceuticals Inc (ARWR) Expected to Post Earnings of -$0.19 Per Share

Equities analysts predict that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will post earnings of ($0.19) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Arrowhead Pharmaceuticals’ earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.21). Arrowhead Pharmaceuticals posted earnings per share of ($0.07) in the same quarter last year, which would suggest a negative year-over-year growth rate of 171.4%. The company is expected to report its next quarterly earnings report on Thursday, August 2nd.

On average, analysts expect that Arrowhead Pharmaceuticals will report full-year earnings of ($0.74) per share for the current year, with EPS estimates ranging from ($0.78) to ($0.69). For the next year, analysts anticipate that the firm will report earnings of ($0.55) per share, with EPS estimates ranging from ($0.92) to $0.89. Zacks’ EPS calculations are an average based on a survey of research firms that follow Arrowhead Pharmaceuticals.

Get Arrowhead Pharmaceuticals alerts:

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01. Arrowhead Pharmaceuticals had a negative net margin of 199.55% and a negative return on equity of 50.05%. The business had revenue of $0.65 million during the quarter, compared to analyst estimates of $4.04 million.

Several equities research analysts recently issued reports on the stock. BidaskClub raised shares of Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 15th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, May 30th. ValuEngine raised shares of Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Piper Jaffray Companies boosted their target price on shares of Arrowhead Pharmaceuticals to $11.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 8th. Finally, Jefferies Financial Group assumed coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, March 27th. They set a “buy” rating and a $10.00 target price for the company. One research analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $9.45.

In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 20,000 shares of the business’s stock in a transaction on Tuesday, June 19th. The shares were sold at an average price of $14.01, for a total transaction of $280,200.00. Following the completion of the transaction, the chief financial officer now owns 330,815 shares of the company’s stock, valued at approximately $4,634,718.15. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Douglas B. Given sold 25,000 shares of the business’s stock in a transaction on Tuesday, April 24th. The stock was sold at an average price of $6.63, for a total transaction of $165,750.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 79,000 shares of company stock valued at $759,950. Company insiders own 4.60% of the company’s stock.

Several large investors have recently bought and sold shares of ARWR. Schwab Charles Investment Management Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 8.8% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 186,381 shares of the biotechnology company’s stock worth $686,000 after purchasing an additional 15,132 shares during the period. Wells Fargo & Company MN increased its holdings in shares of Arrowhead Pharmaceuticals by 237.3% during the 4th quarter. Wells Fargo & Company MN now owns 69,997 shares of the biotechnology company’s stock worth $257,000 after purchasing an additional 49,246 shares during the period. OppenheimerFunds Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 110.0% during the 4th quarter. OppenheimerFunds Inc. now owns 6,300,000 shares of the biotechnology company’s stock worth $23,184,000 after purchasing an additional 3,300,000 shares during the period. Allianz Asset Management GmbH increased its holdings in shares of Arrowhead Pharmaceuticals by 2.2% during the 4th quarter. Allianz Asset Management GmbH now owns 462,105 shares of the biotechnology company’s stock worth $1,701,000 after purchasing an additional 9,985 shares during the period. Finally, BlueCrest Capital Management Ltd bought a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth about $275,000. Institutional investors own 46.31% of the company’s stock.

ARWR stock opened at $13.26 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 10.16 and a quick ratio of 10.16. Arrowhead Pharmaceuticals has a 1 year low of $1.48 and a 1 year high of $14.24. The firm has a market capitalization of $1.15 billion, a P/E ratio of -28.21 and a beta of 2.57.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

Get a free copy of the Zacks research report on Arrowhead Pharmaceuticals (ARWR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

No comments:

Post a Comment